---
title: "Guide to Understanding H. Pylori: What It Is, Why It Matters, and When Treatment Is Necessary"
entity: "blog"
canonical_url: "https://www.drdanwool.com/blog/h-pylori-guide"
markdown_url: "https://www.drdanwool.com/llms/blog/h-pylori-guide"
lastmod: "2026-08-11T13:30:00.000Z"
---

[Home](/Home) > [Articles](https://drdanwool.com/blog) > [H. Pylori Guide](https://drdanwool.com/blog/h-pylori-guide)

Medically reviewed by [Dr. Dan Wool, NMD](https://www.linkedin.com/in/drdanwool/)

 Arizona-licensed Naturopathic Physician and  Gastroenterology Specialist

 Updated: August 11, 2026

- Helicobacter pylori is a gram-negative bacterium infecting approximately 44% of the global population and is the leading cause of peptic ulcer disease and gastric cancer worldwide.
- Most H. pylori infections are asymptomatic for decades but can cause progressive mucosal damage that increases gastric cancer risk by 2 to 6 times if untreated.
- Treatment with bismuth-based quadruple therapy or clarithromycin-triple therapy (where resistance rates are low) achieves eradication in over 90% of cases when completed correctly.
- Not every positive H. pylori test requires immediate aggressive treatment, but any positive test in a person with gastric symptoms, peptic ulcer, or family history of gastric cancer warrants medical evaluation and likely treatment.

Thomas (a pseudonym), a 51-year-old teacher, had been having mild indigestion for years. A routine stool antigen test ordered by his primary care doctor came back positive for H. pylori. His doctor emailed him the result and said he should probably treat it.

Thomas searched online and found wildly conflicting information, ranging from articles saying everyone with H. pylori needs immediate treatment to others arguing it was a harmless commensal organism. He didn't know what to believe or what the stakes really were.

Three months later, he had developed a [peptic ulcer](/blog/peptic-ulcer-disease-pud-conventional-and-natural-treatments). His story illustrates why H. pylori demands thoughtful, informed attention rather than dismissal or panic.

## What Is H. Pylori?

Helicobacter pylori is a gram-negative, microaerophilic spiral bacterium that selectively colonizes the human gastric mucosa, the lining of the stomach. It is uniquely adapted to survive in the highly acidic stomach environment through production of urease, an enzyme that neutralizes gastric acid locally, creating a protected microenvironment in which the bacterium can thrive within the mucosal layer.[1]

H. pylori is one of the most prevalent chronic bacterial infections in human history. A 2023 systematic review and meta-analysis published in Lancet Gastroenterology and Hepatology estimated global H. pylori prevalence at approximately 44%, with significantly higher rates in developing countries in Africa, Latin America, and South Asia, where prevalence often exceeds 70%, and lower rates in high-income countries.[2]

Transmission occurs primarily through the oral-oral and fecal-oral routes, typically in childhood within family units. Contaminated water, crowded living conditions, and inadequate sanitation are the primary drivers of transmission at the population level. Most people acquire H. pylori in childhood, and without treatment, the infection persists for life.

## What Conditions Does H. Pylori Cause?

H. pylori is not an innocent bystander in the stomach. It is the primary cause of chronic active gastritis, the most common form of gastric inflammation worldwide. Its relationship to disease is progressive and depends on both bacterial virulence factors and the host immune response.[1]

- [Peptic ulcer disease:](/blog/peptic-ulcer-disease-pud-conventional-and-natural-treatments) H. pylori is the causative agent in approximately 90% of duodenal ulcers and 70 to 80% of gastric ulcers not caused by [NSAIDs](/blog/nsaids-gut-health). The bacterium disrupts the mucous layer protecting the stomach and duodenal lining, allowing acid to damage the underlying tissue. Eradicating H. pylori heals peptic ulcers in most patients and dramatically reduces their recurrence rate.[2]

- Gastric cancer: This is the most serious consequence of chronic H. pylori infection. H. pylori is classified as a Group 1 carcinogen by the World Health Organization and is the single most important risk factor for non-cardia gastric adenocarcinoma, the third most common cause of cancer-related mortality globally. The pathway from infection to cancer is: chronic active gastritis → atrophic gastritis → intestinal metaplasia → dysplasia → invasive cancer. This cascade takes decades, and eradication before intestinal metaplasia occurs can halt or reverse the process.[2]

- Gastric MALT lymphoma: H. pylori infection is the primary driver of gastric mucosa-associated lymphoid tissue (MALT) lymphoma, a rare but significant malignancy. In many early-stage cases, H. pylori eradication alone produces complete lymphoma remission without chemotherapy.

- [Functional dyspepsia](/blog/functional-dyspepsia): A significant proportion of patients with functional dyspepsia (chronic upper GI discomfort without structural disease) have H. pylori infection. A subset of these patients experience meaningful symptom improvement following eradication, supporting a causal role for H. pylori in some cases of functional dyspepsia.

- Iron deficiency and vitamin B12 deficiency: Chronic H. pylori gastritis impairs iron absorption and may reduce intrinsic factor production, affecting B12 absorption. In patients with unexplained iron or B12 deficiency, H. pylori testing is clinically indicated.

## How Is H. Pylori Diagnosed?

H. pylori can be detected through invasive and non-invasive methods. The choice of test depends on clinical context, prior treatment history, and whether endoscopy is indicated for other reasons.[1]

Non-invasive tests include the urease breath test (UBT) , which has excellent sensitivity and specificity and is the preferred test for active infection assessment and post-treatment eradication confirmation.

The stool antigen test (HpSAg) is equally reliable and is the most convenient test for primary diagnosis and treatment confirmation. Serology (blood antibody testing) is not recommended for post-treatment confirmation because antibodies remain positive long after successful eradication and cannot distinguish active from past infection.

Invasive ( endoscopy ) tests including gastric biopsy, rapid urease test, histology, and bacterial culture are used when endoscopy is being performed for other indications such as ulcer evaluation, anemia workup, or gastric cancer screening.

Important: Both the urea breath test and stool antigen test should be performed at least four weeks after completing H. pylori treatment and two weeks after stopping PPIs to avoid false negative results.

## Potential Benefits of H. Pylori Treatment

Eradicating H. pylori produces documented benefits across multiple outcomes. Peptic ulcer healing is predictable after successful eradication, with recurrence rates dropping from approximately 80% per year to less than 5% per year. The 2023 H. pylori primer in Nature Reviews Disease Primers confirmed that eradication significantly reduces gastric cancer incidence, particularly when performed before the development of intestinal metaplasia.[2]

In gastric MALT lymphoma, eradication is a standard first-line treatment with complete remission rates of 60 to 80% in H. pylori-positive, low-grade localized cases. For functional dyspepsia, test-and-treat strategies in H. pylori-positive patients produce symptomatic benefit in a subset of patients and are recommended by major guidelines before empiric PPI therapy.

## Important Considerations for H. Pylori Treatment

The single most important challenge in H. pylori management today is antibiotic resistance. Resistance to clarithromycin, the cornerstone antibiotic of standard triple therapy, now exceeds 15 to 20% in many regions, and resistance to metronidazole is even higher. This has driven a shift in treatment guidelines toward bismuth-based quadruple therapy as the preferred first-line regimen in regions with high clarithromycin resistance.[2]

When standard triple therapy fails, the choice of rescue regimen should ideally be guided by antibiotic susceptibility testing through culture or molecular testing of gastric biopsy specimens. Choosing a second regimen empirically after treatment failure increases the risk of creating multi-drug-resistant infections.

Not everyone who tests positive for H. pylori in the absence of symptoms requires immediate treatment, but asymptomatic carriers still carry increased long-term cancer risk. The decision to treat should be made in clinical context with appropriate evaluation.

## What Research Says About H. Pylori

A 2024 comprehensive review published in Microorganisms confirmed that H. pylori is a pervasive pathogen infecting nearly 50% of the world's population, with its link to gastric cancer representing one of the most important preventable causes of cancer mortality globally.[2] The review documented the full pathogenesis pathway from colonization to carcinogenesis and outlined current treatment options including bismuth quadruple therapy as the preferred approach in areas of rising antibiotic resistance.

The landmark 2023 Nature Reviews Disease Primers H. pylori paper updated the global understanding of eradication strategies, confirming that the dramatic increase in resistance to clarithromycin and metronidazole demands antibiotic susceptibility testing and antibiotic stewardship in H. pylori management.[1]

Research has also clarified the screen-and-treat strategy for gastric cancer prevention. In high-prevalence populations, mass eradication programs have been shown to reduce gastric cancer incidence by 33 to 55% over periods of 5 to 10 years after treatment, establishing H. pylori eradication as a genuine cancer prevention strategy.[2]

## What to Expect With H. Pylori Treatment

The standard bismuth-based quadruple therapy, consisting of a proton pump inhibitor, bismuth subsalicylate, tetracycline, and metronidazole for 10-14 days, produces eradication rates exceeding 90% in most populations. Side effects including dark stools, metallic taste, nausea, and fatigue are common and typically resolve after treatment ends.

Eradication confirmation is essential and should be performed via urea breath test or stool antigen test at minimum 4 weeks after completing therapy. A positive post-treatment test confirms treatment failure and should prompt a different second-line regimen. Repeat the same regimen again after first failure is not recommended.

## Natural and Integrative Approaches to H. Pylori Support

Several natural compounds have demonstrated activity against H. pylori and may serve as adjuncts to or, in very mild cases, alternatives to antibiotic therapy.

- Mastic gum (Pistacia lentiscus resin) has multiple published studies showing antibacterial activity against H. pylori including clarithromycin-resistant strains.

- Sulforaphane from broccoli sprouts has been studied as a direct antimicrobial against H. pylori and as a cancer-preventive agent in the gastric mucosa.

- Berberine, [probiotics containing Saccharomyces boulardii](/blog/saccromyces-boulardii) and Lactobacillus reuteri, and N-acetylcysteine (as a biofilm disruptor) are used as adjunctive therapies alongside antibiotic protocols to improve eradication rates and reduce side effect burden.

- [Zinc carnosine](/blog/zinc-carnosine) supports gastric mucosal healing after eradication.

## The Bottom Line on H. Pylori

H. pylori is not a trivial finding on a lab report -- but context is everything. It's the world's most common chronic bacterial infection but also the most important preventable risk factor for gastric cancer. In the right clinical context, eradication is one of the most evidence-supported and impactful interventions in all of preventive medicine.

Whether you are symptomatic or asymptomatic, a positive test deserves thoughtful evaluation and a plan that accounts for your personal risk profile, treatment history, and antibiotic resistance patterns in your region.

## Frequently Asked Questions about H. Pylori

### Does everyone who tests positive for H. pylori need treatment?

Quick Answer: Not always, but most guidelines recommend treating all detected infections due to the long-term cancer risk, particularly in those with symptoms, [ulcers](/blog/peptic-ulcer-disease-pud-conventional-and-natural-treatments), or family history of gastric cancer.

Full Answer: Current international guidelines, including from the American College of Gastroenterology and the European Helicobacter Study Group, generally recommend treating all confirmed H. pylori infections in adults, even asymptomatic ones, because of the cumulative cancer risk and the availability of effective treatment. The exceptions include certain low-risk, elderly, asymptomatic patients where treatment benefit versus risk may be reassessed individually. The decision is best made with a clinician who understands both your personal risk factors and your regional antibiotic resistance patterns.

### Can H. pylori cause anxiety, fatigue, or brain fog?

Quick Answer: Emerging research suggests H. pylori may contribute to systemic inflammation, nutrient deficiencies, and gut microbiome disruption that affect mood, energy, and cognition beyond the stomach.

Full Answer: While the primary effects of H. pylori are gastric, chronic infection creates a persistent inflammatory state that affects systemic health. Iron deficiency and B12 deficiency from impaired gastric absorption can cause fatigue, brain fog, and mood changes. Some research suggests H. pylori may affect [gut serotonin](/blog/ssris-gut-health) production and the gut-brain axis more broadly. Post-eradication improvements in energy and cognition are reported by many patients but have not been definitively confirmed in controlled trials. The systemic effects of chronic H. pylori infection are likely underestimated.

### How do you know if you have H. pylori without a test?

Quick Answer: You often cannot know without testing. Most infections are asymptomatic for years. Upper abdominal pain, [bloating](/bloating-treatment-scottsdale), and nausea after meals are suggestive but nonspecific symptoms.

Full Answer: H. pylori infection is notoriously asymptomatic in the majority of carriers. When symptoms do occur, they typically include recurrent upper abdominal pain or discomfort, early satiety, nausea, bloating, and burping. These symptoms overlap with many other conditions. The only reliable way to diagnose H. pylori is through the urea breath test, stool antigen test, or endoscopic biopsy. Any person with persistent unexplained upper GI symptoms, unexplained iron deficiency, or a family history of gastric cancer should be tested.

### How long does H. pylori treatment take?

Quick Answer: Standard treatment courses are 10-14 days. Eradication confirmation testing should be done at least 4 weeks after completing treatment.

Full Answer: [Bismuth-based quadruple therapy](/blog/bismuth-gut-health-biofilm) is typically prescribed for 10-14 days. Clarithromycin-based triple therapy is given for 14 days. Sequential therapy protocols may differ. Completing the full course is essential for eradication success. Stopping early significantly increases treatment failure risk. After completing the course, most practitioners wait at least 4 weeks and ensure the patient has been off PPIs for 2 weeks before performing a confirmation test to avoid false negatives.

### Can H. pylori come back after successful eradication?

Quick Answer: Yes, through reinfection, though recurrence rates in developed countries are low (under 1% per year). Reinfection is more common in high-prevalence environments with ongoing exposure risk.

Full Answer: True recurrence of H. pylori after confirmed eradication is usually from re-exposure to the bacteria rather than treatment failure. In developed countries with good sanitation, reinfection rates are low (approximately 1% per year). In developing countries with high transmission risk, reinfection rates can be 10 to 15% per year or higher. Family members of H. pylori-positive patients should be considered for testing because intrafamilial transmission is the primary route of infection and reinfection.

### Is it possible to have H. pylori and IBS at the same time?

Quick Answer: Yes. H. pylori and [IBS](/blog/ibs-d-guide) frequently coexist, and active H. pylori infection can worsen IBS symptoms through inflammation, altered motility, and microbiome disruption.

Full Answer: H. pylori infection causes active gastritis and disrupts gastric motility, which can amplify symptoms that overlap with [IBS](/ibs-treatment) such as [bloating](/bloating-treatment-scottsdale), altered bowel habits, and abdominal discomfort. In H. pylori-positive patients with concurrent IBS symptoms, eradicating the infection sometimes produces significant improvement in functional symptoms beyond just ulcer healing. It is therefore clinically important to test for H. pylori in IBS patients, particularly those with upper GI symptoms or who have not responded to standard IBS management.

## Are You Ready to Fix Your Gut?

Struggling with your gut health? [Dr. Dan Wool](/about) offers personalized, natural solutions at his Scottsdale naturopathic practice. [Book a free 15 minute discovery call](/booking) today and take the first step toward lasting digestive relief.

Disclaimer:

The information provided on this page is for educational purposes only and is not intended as medical advice, diagnosis, or treatment. Dr. Dan Wool nor his affiliates do not make claims about the effectiveness of supplements, peptides, hormones or other therapies outside of the contexts supported by cited clinical evidence and regulatory approval. Always consult a qualified healthcare provider before starting, changing, or stopping any medical or wellness program.

About the Author

## Dr. Dan Wool, NMD

[Dr. Dan Wool](/about) is a naturopathic doctor who specializes in gastroenterology, hormones and men's health in Scottsdale, Arizona. [Set up a free 15-minute discovery call with Dr. Wool today! ](https://drdanwool.com/booking)

[Read more about Dr. Wool's Gut Health Journey](/about)

## References:

1. [Malfertheiner P, Camargo MC, El-Omar E, et al. Helicobacter pylori infection. Nat Rev Dis Primers. 2023;9(1):19. https://pubmed.ncbi.nlm.nih.gov/37081005/](https://pubmed.ncbi.nlm.nih.gov/37081005/)

2. [Alfizah H, et al. Helicobacter pylori: A Contemporary Perspective on Pathogenesis, Diagnosis and Treatment Strategies. Microorganisms. 2024;12(1):222. https://pmc.ncbi.nlm.nih.gov/articles/PMC10818838/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10818838/)

3. [Sun Q, et al. Helicobacter pylori infection: a dynamic process from diagnosis to treatment. Front Cell Infect Microbiol. 2023;13:1257817. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621068/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621068/)

4. [Öztekin M, et al. Overview of Helicobacter pylori Infection: Clinical Features, Treatment, and Nutritional Aspects. Diseases. 2021;9(4):66. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8544542/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8544542/)